Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.
If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.
* Price is subject to applicable taxes.
Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.
(TheNewswire)
Vancouver, British Columbia – TheNewswire - September
11th, 2019 – AREV Brands
International Ltd. ("AREV" or the “Company”)
(CNSX:AREV.CN) is pleased to announce that it is
negotiating to acquire 50 per cent of Lighthouse Genomics Inc.
Lighthouse will remain an independent operating entity with voting
control and an agreement to provide AREV holdings with preferential
access to genomic analysis to inform AREV breeding operations with
advanced genetic science.
AREV, a cannabis integrator, conducts extensive breeding research and
development to produce proprietary genetic assets through
its holdings in BC Bud
Depot. The Lighthouse acquisition complements the Company’s purchase
of its largest holding, BC Bud Depot assets, which include a seed bank
considered to be a world-class genetic resource, as previously
announced September 7, 2018. The strategic investment in Lighthouse
Genomics Inc. strengthens AREV’s position as an international leader
in cannabis genetic research and breeding.
AREV’s programs operated by BC Bud Depot will utilize
Lighthouse’s proprietary technologies to accelerate breeding of new
genetic assets through oversight of the genetic basis of traits in
cannabis. Lighthouse’s
industry-leading technologies include the Lighthouse Cannabis Assay™
(LCA), which captures 40,000 single nucleotide polymorphisms (SNPs)
selected for high relevance within the cannabis genome. The LCA is
considered the most comprehensive SNP genotype array chip for cannabis
currently available worldwide. Lighthouse has also produced a
proprietary bioinformatics software pipeline to analyze and interpret
data produced by LCA genotyping or by Whole Genome Sequencing. These
data-capture and analytic technologies provide AREV with an
unprecedented opportunity to apply strategic genomic intelligence to
producing rare and stable traits in new genetic assets, developed with
speed and precision far surpassing conventional plant-breeding
practices.
Timothy Harvey, CEO of Lighthouse Genomics, stated,
“Genetic oversight is an indispensable tool for developing cannabis
varieties with production efficiencies and rare chemical signatures
that target specific desired outcomes. We offer tools and techniques
that allow cannabis companies to lead and compete as the industry
transitions to a science-based era. The Lighthouse Cannabis Assay™
can be used to screen populations to detect infrequent allelic forms,
and to select breeding partners for reproductive stability in genes
that encode for traits not commonly expressed in the broader
population. The LCA captures data from approximately 5000 genes of
interest, including dozens of cannabinoid and terpene synthase genes,
precursor genes and genes associated with crop yields and flower size.
We provide AREV the opportunity to analyze the allelic forms and
frequencies that underly hidden diversity within the cannabis gene
pool – in other words, to prospect for value on the genetic
frontier.”
Harvey noted that Lighthouse continues to support
companies industry-wide while maintaining a rigorous data security and
protection policy. “Only Lighthouse bioinformaticians have access to
our genome database,” Harvey stated. “However, all clients benefit
as our database grows. Extensive genotyping by a company such as BC
Bud Depot causes the Lighthouse database to become a more precise tool
for measuring genetic novelty and expressions of value in the cannabis
genome. This partnership is a benefit to all existing and future
clients of our company. AREV is contributing to the advancement of
cannabis science.”
Mike Withrow, CEO for AREV Brands International,
states, “Acquiring of 50% of Lighthouse solidifies our leadership in
the field of cannabis genetics. This is a high-magnitude acquisition
allowing us to pair BC Bud Depot’s vast genetic reservoir with
Lighthouse technologies, to maximum advantage. Our enhanced breeding
programs will ensure that BC Bud Depot genetics continue to raise the
bar for quality in the industry. We will select our cultivation
partners based on their ability to bring out the very best in these
strains.”
As previously announced April 11 2019
BC Bud Depot moves to improve the variety and qualities of cannabis strains made available to the medicinal and recreational markets by Licensed Producers in Canada. BC Bud Depot contracted Lighthouse to conduct Whole Genome Sequencing on the first ten select BC Bud Depot cultivars. Lighthouse has provided BC Bud Depot extensive consulting and two forms of reporting: a Genetic Assets Overview (now known as the Genetic Assets Population Report) providing oversight to the entire tested BC Bud Depot gene pool, and a Genovar Report for each individual plant sequenced.
As previously announced in
May 2019
Lighthouse has issued certification documents to BC Bud Depot for the master plants of 10 genovars, clone groups that share the common genome of the individual plant tested in the certification process. The BC Bud Depot genovars are elite lineages selected for traits desirable in master breeding stock used for producing seeds and new cannabis varieties.
For further information, contact Mike Withrow,
[email protected]
On behalf of the Board,
Mike Withrow
CEO & Director
About AREV Brands International Ltd.
AREV Brands International Ltd. (“AREV”) produces and delivers
functional compounds and ingredients from its world-class extraction
systems. AREV is revolutionizing the current delivery method of
terpenes, cannabinoids and flavonoids. These premium ingredients and
formulations are used in products targeted for sale in the natural
health, medical, functional food, nutraceutical, sport nutrition and
bioceutical markets. AREV innovates through extraction to produce
extracts from specific selected plant and exude from trees that
address 5 areas of health including Anxiety, Pain Management,
Insomnia, Central Nervous System Disorders & Libido.
About Lighthouse Genomics Inc.
Lighthouse Genomics Inc. (“Lighthouse”)
provides genetic analysis reports to the cannabis industry and
certification of the genetic identity of cannabis varieties, called
genovars. Lighthouse owns proprietary technologies including analytics
software and the design of the industry’s most advanced SNP genotype
array. These technologies are used by clients to gain greater
knowledge of their genetic assets, to document their claim to genetic
IP, to optimize breeding programs and to verify the genetic
consistency of product batches to the standards of pharmacy retailers.
Lighthouse Genomics is proud to collaborate with a variety of academic
institutions, producers and breeders, and to conduct significant
internal research and development in the interests of advancing
cannabis science. Recognizing that the resilience of the cannabis
industry relies upon diversity within the cannabis gene pool,
Lighthouse considers it their mission to document and amplify that
genetic diversity.
NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
FORWARD LOOKING INFORMATION
Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws. This press release contains forward-looking statements. The use of any of the words "anticipate", "continue", "estimate", "expect", "may", "will", "project", "should", "believe" and similar expressions are intended to identify forward-looking statements. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks various risk factors discussed in the Company’s Management’s Discussion and Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2019 TheNewswire - All rights reserved.